fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Hostility linked with higher risk of death after second heart attacks

Written by | 5 Oct 2020

Heart attack patients who are sarcastic or irritable could be putting their health at risk, according to research published today in the European Journal of Cardiovascular Nursing, a journal… read more.

Depression, but not anxiety, linked with inflammation and metabolic change

Written by | 4 Oct 2020

Anxiety and depression are often linked and assumed to be closely related, but now research has shown for the first time that depression and anxiety have different biochemical… read more.

Doctors develop system which can predict Bipolar Disorder 4 years before onset

Written by | 1 Oct 2020

An international team of doctors have developed a machine learning system which can predict the development of Bipolar Disorder up to 4 years before onset in young people:… read more.

Older people with early, asymptomatic Alzheimer’s at risk of falls

Written by | 23 Sep 2020

Falls are the leading cause of fatal injuries in older adults, causing more than 800,000 hospitalizations and about 30,000 deaths in the U.S. every year. Some risk factors… read more.

Top-line results from the phase III CLARITY study evaluating pimavanserin for the adjunctive treatment of major depressive disorder.-Acadia Pharmaceuticals.

Written by | 23 Jul 2020

Acadia Pharmaceuticals Inc. announced top-line results from its 298 patient Phase III CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating the efficacy, safety and tolerability of… read more.

Soleno Therapeutics announces top-line results from phase III trial of DCCR for treatment of Prader-Willi syndrome.

Written by | 14 Jun 2020

Soleno Therapeutics, Inc. announced top-line results from the Company’s Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome… read more.

STRIDE-1 Phase III Trial of AXS 05 meets key secondary endpoints in depression.- Axsome Therapeutics

Written by | 1 Apr 2020

Axsome Therapeutics announced that AXS 05 (bupropion + dextromethorphan) met key secondary endpoints in the STRIDE-1 trial by rapidly and statistically significantly improving symptoms of depression on the… read more.

DDW 2018: Quality of life for IBD patients

Written by | 2 Oct 2018

Inflammatory bowel disease can have a detrimental impact of health-related quality of life, and reducing the physical and psychological disease burden is an important therapeutic target. Patient-reported outcomes… read more.

DDW 2018: Choice in patient management

Written by | 2 Oct 2018

IBD specialists have more treatment options than ever before; yet the optimal use of many agents, old as well as new, remains to be defined. A plenary session… read more.

Denmark: 1 in 4 people leave work a year after a heart attack

Written by | 11 May 2018

One in four people leave their job within a year of returning to work after having a heart attack, according to a study from Denmark in the Journal… read more.

BSH 2017: Cancer-related chronic fatique – internet and digital technology solutions

Written by | 14 Apr 2017

Chronic, cancer-related fatigue (CRF) is associated with a sudden- onset, profound lack of energy that is not relieved by rest. It is different from the fatigue experienced by… read more.

Is ‘online therapy’ making patients worse?

Written by | 13 Mar 2017

Scientists in Sweden are studying whether web-based cognitive behavioural therapy (CBT) is ineffective in some people, potentially making patients worse. The psychologist behind the research say that while… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.